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 Reduced intensity conditioning
a b s t r a c t
Allogeneic transplantation (allo) of patients with multiple myeloma is a controversial
treatment due to high transplant related mortality (TRM) with myeloablative conditio-
ning before the transplant. However, using reduced intensity conditioning (RIC) and pre-
vious autologous transplantation (auto) has dramatically reduced TRM. This, in combina-
tion with a lower relapse/progression rate, has in two out of six prospective studies
resulted in prolongation of both progression free survival (PFS) and overall survival (OS)
as compared to auto. No prospective study has proven auto – single or tandem – to be
better than the auto/RICallo modality. The rapid development of relatively effective drugs
in multiple myeloma has made most centers reluctant to use upfront RICallo. Conside-
ring the initial TRM of 12–16% with this treatment, it is now mainly used after progres-
sion-relapse following auto. New studies including more effective GVHD prevention and
combination of allo with new drugs in the conditioning and as maintenance therapy are
ongoing or in planning. Until clear advantageous results have been shown it seems
reasonable to use the auto/RICallo procedure mainly in relapsed patients or upfront in
patients with poor prognostic parameters such as del17p, del8p or gain 1q. The prospects
for long-term survival or perhaps cure for a fraction of patients seem highest following
some kind of allo.
© 2015 Polskie Towarzystwo Hematologów i Transfuzjologów, Instytut Hematologii i
Transfuzjologii. Published by Elsevier Sp. z o.o. All rights reserved.Introduction
Based on a few initial promising case reports indicating
possible cure with allogeneic transplantation (allo) of multiple
myeloma the EBMT (the European Group for Blood* [29_TD$DIFF]Correspondence to: Department of Medicine, Karolinska Institutet, H
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z o.o. All rights reserved.and Marrow Transplantation) started to perform allo in the
early 1980th, and results of the first large series of patients
were published in 1987 [1] and 1991 [2]. A fraction of patients
entered complete hematologic remission (CR) and CR was
demonstrated to be the most important prognostic factor for
long-term survival [3]. However, the high-dose myeloablativeuddinge, SE 14186 [30_TD$DIFF]Stockholm, Sweden. Tel.: +46 706655284; [31_TD$DIFF]
w, Instytut Hematologii i Transfuzjologii. Published by Elsevier Sp.
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mortality (TRM) – up to 40% after upfront treatment [3]. In
attempts to reduce the TRM the Seattle Group started
a program using very low conditioning dosages – down to
200 cGy total body irradiation (TBI), the idea being to utilize
the well documented graft-versus-myeloma (GVM) effect [4–6]
for tumor cell killing. Recent prospective trials have mainly
used variants of this nonmyeloablative, reduced intensity
conditioning (RIC) approach, but preceded by an autologous
transplant (auto) for tumor cell reduction. Until recently these
studies used the VAD (vincristine + adriamycine + dexametha-
sone) or similar regimens for induction. Ongoing studies and [36_TD$DIFF]
those in planning are including novel drugs like thalidomide,
bortezomib and lenalidomide in attempt to improve results.How to perform an allogeneic transplantation in
multiple myeloma
Myeloablative conditioning
Myeloablative conditioning has mainly been abandoned due
to the high TRM. The primary goal of myeloablative con-
ditioning is to eradicate the disease and rescue the patient
with the normal cells in the allogeneic graft. However, in
addition, a GVM effect is well documented [4–6]. The most
common myeloablative conditioning regimens are TBI 10–12
Gray fractionated or unfractionated with lung shielding [2,
3]. Many other conditioning regimens including high dose
melphalan, and cyclophosphamide have been used as well
[7–9]. Myeloablative conditioning allo is associated with
lower relapse rate as compared to both RICallo and high
dose conditioning auto but the TRM is higher and amounted
to of [37_TD$DIFF] 0–40% in earlier studies, mainly due to severe graft-
versus-host disease (GVHD). Despite the lower relapse rate
the progression-free survival (PFS) and overall survival (OS)
[3, 10] were therefore generally poorer with myeloablative
conditioning allo. However, there were subgroups of
patients [38_TD$DIFF]who did better, e.g. females with a female donor
[11, 12], but still the TRM was high. Thus, despite improve-
ment in results with time due to better supportive treat-
ment [13], high CR rate of 50–60% [3, 14], higher rates of
molecular remissions than after auto [15] and comparatively
low relapse/progression rate, the high TRM has discouraged
from the use of myeloablative conditioning.Reduced intensity (nonmyelablative) conditioning
(RIC)
The idea of using nonmyeloablative reduced intensity con-
ditioning (RIC) is to take advantage of the GVM effect for
tumor killing and reduce TRM by lowering the irradiation
and/or cytotoxic drug dose. Experimental canine transplant
studies [16] by the Seattle Group showed that allogeneic
engraftment [17] was possible with only 200 cGy irradiation
and GVHD prophylaxis with mycophenylate moffetil and
cyclosporine [18]. In a clinical study of 18 patients with
refractory disease or failed prior autologous transplantation
2 entered CR and 3 further patients had a partial responsewith this approach. It was assumed that the response was
mainly due to the GVM effect.
Since these crucial results appeared numerous phase
I and II RICallo studies have been performed [7, 18–28]. In
addition there are six prospective upfront studies with
somewhat different design comparing the combination
auto/RICallo to auto or auto/auto (Table I). All of them were
based on the availability of an HLA matched sibling donor
[29–37]. In four of the studies TBI 200 cGY was used for the
RICallo conditioning as in the Seattle study. One – the EBMT
study – used as well fludarabin 30 mg/m2 [39_TD$DIFF] 3 before irradia-
tion. The IFM study used a combination of fludarabine, low
dose busulfan and ATG and the PETHEMA group Melphalan
140 mg/m2 plus fludarabine. In five of the studies, the
control group was tandem autologous transplantation in
those patients [40_TD$DIFF]who lacked a donor, while in one of the
studies – the EBMT study – either single or tandem auto-
logous transplantation was used. The induction treatment
was VAD (vincristine + adriamycin + dexamethasone), thali-
domide and dexamethasone, or similar combinations in all
studies, and the conditioning for the initial autologous
transplant was 200 mg/m2 melphalan.
The IFM study [31, 32][1_TD$DIFF] included 219 patients [5_TD$DIFF]without [6_TD$DIFF]
(tandem auto group) and 65 [7_TD$DIFF]with [8_TD$DIFF]an [9_TD$DIFF]identical sibling donor [10_TD$DIFF]
(auto/RICallo [11_TD$DIFF]group). [12_TD$DIFF]All [13_TD$DIFF]patients had high risk disease as
defined by beta2-microglobulin of more than 3 mg/L, and
deletion of chromosome 13. On an intention to treat basis
the median event-free survival was 19 versus 22 months
and the OS 34 versus 48 months in the auto/RICallo and
auto/auto groups respectively, i.e. a trend for inferior OS in
the auto/RICallo group ([43_TD$DIFF]p = 0.07). The use of antithymocyte
globulin – Imtix Genzyme (2.5 mg/kg/day during 5 days) for
GVHD prevention – and busulfan and fludarabine for con-
ditioning might have played a role for the trend for poorer
outcome with auto/RICallo.
The Italian study [33, 37] comprised 245 patients enrolled
at time of diagnosis. Eighty out of 162 patients who under-
went HLA typing had an HLA-identical sibling donor and 58
out of these 80 patients underwent the auto/RICallo proce-
dure. They were compared to 46 patients without and HLA
identical sibling who received auto/auto. On an intention to
treat analysis the median event-free survival in the auto/
RICallo group was 35 months, as compared to 29 months in
the auto/auto group ( [43_TD$DIFF]p = 0.02). The median OS was 80
months versus 54 months, respectively ( [44_TD$DIFF]p = 0.01). Long-term
intent to treat analysis with patients more than seven years
from diagnosis continue to demonstrate an OS benefit for
auto/[14_TD$DIFF]RICallo with median survival not reached versus 4.2
years in the auto/auto arm ( [45_TD$DIFF]p = 0.001) [37].
The Spanish PETHEMA study [35] – was relatively small
in that it included only 25 patients in the auto/RIC arm
compared to 85 receiving auto/auto. Patients less than
seventy who failed to achieve a CR or nCR after the initial
autologous transplant were eligible for second transplant.
The median time for PFS and OS had not been reached in
the auto/RICallo group, while it was 31 months ( [43_TD$DIFF]p = 0.08) and
58 months ( [43_TD$DIFF]p = 0.9), respectively, in the auto/auto group.
Thus, this study indicated a trend toward [46_TD$DIFF]superior outcome
with the auto/RICallo procedure in patients who did not
reach CR after initial auto.






















Garban et al., 2006 and
Moreau et al., 2008
[31, 32]
Flu 25 mg/m2 [3_TD$DIFF]
5 days + BU 2 mg/kg 




11% 19 m 34 m
Bruno et al., 2007 [33] TBI 2 Gy [5_TD$DIFF]Auto/RICallo 80 Prospective
upfront
16% 6.5 y 35 m Median not
reached
Lokhorst et al., 2012 [34] TBI 2 Gy [5_TD$DIFF]Auto/RICallo 138 Prospective
upfront
11% 1 y 28% 6 y 55% 6 y
















Björkstrand et al., 2011
and Gahrton
et al., 2013 [29, 30]
Flu 30 mg/m2 [8_TD$DIFF] 3 d
+ TBI 2 Gy
Auto/RICallo 108 Prospective
upfront
12% 2 y 43% 3 y 71% 3 y
[9_TD$DIFF]15% 5 y 22% 8 y 49% 8 y
Rosinol et al., 2008 [35] Flu 25 mg/m2 [10_TD$DIFF] 5d









Crawley et al., 2007 [7] Flu [11_TD$DIFF]+ TBI Flu + Mel
Flu + Bu  T-cell depl
Auto/RICallo or
RICallo alone
Retrospective 24% 2 y 19% 3 y 38% 3 y
[12_TD$DIFF]516 (RIC 62%)
Progressive 28%










[14_TD$DIFF] 934 (22%) Upfront (25%) 43% 39%






1588 (71%) >8 m post
1 auto (29%)
26% 33%
[17_TD$DIFF]588 (84%) <8 m post
2 auto (17%)
28% 31%
[18_TD$DIFF]930 (68%) >8 m post
2 auto (31%)
24% 29%
[19_TD$DIFF]296 (71%) After 3 auto (27%) 15% 23%
Kröger et al., 2010 [19] Mel 140 mg/m2 + [20_TD$DIFF] lu
30 mg2  3d + ATG
20 mg/kg  3d





[21_TD$DIFF]Efebere et al., 2010 [69] Mel 90–140 mg/m2 + [22_TD$DIFF] lu
90–120 mg/m2  ATG
RICallo 55 Prospective
Relapse
25% 19% 2 y 32% 2 y
Shimoni et al., 2010 [71] Mel + Flu based RICallo 50 Retrospective
Refractory/ [23_TD$DIFF]Relapse
26% 26% 6.4 y 34% 6.4 y
Patriarca et al., 2012 [39] Flu + Mel + Thiotepa
(41%) Flu [24_TD$DIFF]+ TBI 2 Gy (35%)




22% 42% 2 y 52% 2 y
Karlin et al., 2011 [70] TBI 2 Gy Auto/RICallo 23 Retrospective
Relapse
17% 36.8 m 60 m
RIC = reduced intensity conditioning; NRM = non relapse mortality; TRM = treatment related mortality; PFS [25_TD$DIFF]= progression free survival; OS [26_TD$DIFF]
= overall survival; Flu = fludarabine; Bu [27_TD$DIFF]= busulphan; TBI = total body irradiation; ATG = antithymocyte globulin; CR = complete remission;
nCR = near complete remission [28_TD$DIFF].
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patients of whom 122 had an HLA identical sibling donor. Of
these 122 patients, 99 received an HLA-identical sibling
transplant, while those without a donor received further
treatment with thalidomide maintenance or a second auto.
No significant difference in PFS or OS was seen when
analyzed on an intention to treat basis. However, the relapse
rate was significantly lower in the donor group. Although not
significant, the six-year PFS was 28% in the donor group and
22% in the no donor group ([43_TD$DIFF]p = 0.19). On an as treated
analysis, when those patients [47_TD$DIFF]who had really received
a RICallo transplant ([48_TD$DIFF]n = 99) were compared to those who
continued maintenance or received a second auto transplant,
there was a significant advantage in PFS for the RICallo
patients.
The American BMT CTN 0102 study [36] – comprised 710
patients (625 standard risk and 85 high risk). Patients [49_TD$DIFF]<70
years, between 2 and 10 months of initiation of myeloma
therapy were eligible for enrollment and assigned to either
auto/auto with high dose melphalan (200 mg/m2) or auto/
RICallo with single dose 2 Gy total body irradiation condi-
tioning. Standard risk myeloma was defined as beta2-micro-
globulin <3.0 and absence of deletion 13 by classic
karyotyping. By intent to treat analysis there was no
significant difference in three year PFS between the auto/
auto and auto/RICallo at 46% [50_TD$DIFF]versus 43% (p = 0.671) respec-
tively. Three year OS was 80% with auto/auto versus 77%
with auto/RICallo ( [43_TD$DIFF]p = 0.19). A subgroup analysis was done
on high risk patients to assess if these patients who had
a higher risk of relapse would benefit from the auto/allo
approach. No significant difference was seen with a three
year PFS of 40% with auto/RICallo versus 33% with auto/[51_TD$DIFF]auto
(p = 0.74) and OS of 59% versus 67% ( [43_TD$DIFF]p = 0.46) respectively.
The EBMT study [29, 30] – comprised 357 myeloma
patients from 23 centers. Patients up to age 69 with an HLA-
identical sibling were allocated to the auto/RICallo group
([48_TD$DIFF]n = 108), and those without to auto ([48_TD$DIFF]n = 249), either as a single
or tandem transplant. The study was originally published in
2011 [30] and was updated in 2013 [29] with the median
follow-up now 96 months. At this time, both PFS and OS were
significantly superior in the auto/RICallo group as compared
to the auto group. On an intention to treat analysis, PFS with
auto/[52_TD$DIFF]RICallo was 22%, as compared to 12% with auto
(p = 0.012), and OS was 49%, as compared to 36% with auto
(p = 0.020). Despite the higher nonrelapse mortality of 13% at
36 months in the auto/RICallo group as compared to 3% in
the auto group, the lower relapse rate of 60% at 96 months in
the auto/RIC allo group versus 82% in the auto group
translated into superior PFS and OS. However, at 36 months,
there was no significant difference between the two groups,
i.e. PFS was 43% versus 39% and OS 75% versus 68% in auto/
RICallo and auto respectively. Thus, the conclusion was that
long-term follow-up is necessary to see the benefits of the
auto/RICallo procedure as compared to the auto procedure. In
a subgroup analysis it was shown that CR was the important
factor in achieving long-term PFS, in both groups, but a CR
obtained with auto/RICallo was sustained longer than if
obtained after auto/auto ([43_TD$DIFF]p = 0.008) [38].
Although two of the six prospective studies show super-
ior outcome with the auto/RICallo procedure as compared toauto or auto/auto the studies are not designed to give
information about the impact of the type of conditioning
regimen (Table I). However, in the four studies that used TBI
2 Gy [29, 33, 34, 36] with or without fludarabine, the results
are initially similar. The three-year PFS/OS survival was not
significantly different between auto/RICallo and auto (or
auto/auto) in any of these studies. The six-year OS was very
similar for both auto/RICallo and auto (auto/auto in the
HOVON study) in the HOVON and EBMT studies[53_TD$DIFF], i.e. 61%
versus 51% compared to 64% versus 57% respectively,
however the difference in OS was only significant in the
EBMT study. The long-term superior survival with auto/
RICallo in the Italian study appears to be in the same range
as in the EBMT study. A longer follow[54_TD$DIFF]-up of the BMT CTN
has not yet been published. Thus total body irradiation
200 cGy with or without fludarabine seems to be
a reasonable conditioning for RICallo. Other regimens like
low dose busulfan + fludarabine, low or intermediate dose
melphalan + fludarabine or treosulfan + fludarabine may
well be used. However no prospective comparison between
different conditioning regimens has been performed.Novel drugs as maintenance and at progression/
relapse after allogeneic transplantation
The long[32_TD$DIFF]-term prospective up front studies are hampered by
not having included novel drugs in the conditioning regi-
men. In a few retrospective studies of RICallo for treatment
of progression/relapse novel drugs have been included
before or after the conditioning. However there has been
no comparison between different conditioning regimens.
Patriarca et al [55_TD$DIFF]. [39] included 169 consecutive patients in
a retrospective multicenter study comparing the outcome of
salvage auto versus salvage RICallo[56_TD$DIFF]. All patients received
salvage treatment with thalidomide, lenalidomide and/or
bortezomib. Seventy-five patients had an HLA matched
donor of which 68 underwent RICallo transplantation
including 24 from an HLA-identical sibling. The two-year
NRM was 22% in the donor group and 1% in the no donor
auto group. The two-year PFS was 42% in the donor group
as compared to 18% in the no donor group, but there was
no significant difference in the two-year OS between the
two groups (54% and 53%, respectively). The impact of
including new drugs in the regimen was not evaluated.
Consolidation and maintenance treatment following auto is
standard in many centers. However, in the allo setting
studies on maintenance are scarce. The HOVON study used
thalidomide for maintenance, as did the BMT CTN trial. In
both trials the authors concluded that they could not see
a significant effect of thalidomide in this setting. However,
in the HOVON trial thalidomide was used in both treatment
arms, therefore its efficacy could hardly be evaluated and in
the BMT CTN trial over 80% of patients were unable to
complete the planned thalidomide maintenance. In addition
in all the upfront prospective trials the extent to which the
new drugs were used at progression or relapse was not
analyzed, since treatment after progression was optional.
Novel drugs have been used in phase II studies both at
progression and for maintenance. In one study [40] low dose
a c t a h a ema t o l o g i c a p o l on i c a 4 6 ( 2 0 1 5 ) 2 2 4 – 2 3 2228thalidomide was used for treatment of 18 patients with
progressive or residual disease after allo and before donor
lymphocyte infusions (DLI). The overall response rate was
68% with 22% CR. In another study [41] thalidomide was
used to treat 31 patients with progression after allo. Nine
out of 31 patients responded, and three of [57_TD$DIFF]these came with
a very good partial response. These responses were inter-
preted as partly due to a GVM effect since they were
associated with chronic GVHD. Thus thalidomide may have
a place in treatment of relapse/progression after allo, but
the value of its use as maintenance or in the conditioning is
not known.
Bortezomib appears to be effective in association with
allo, due to a GVHD preventive effect, while presumably still
preserving the GVM effect [42–44]. Its additional antimye-
loma effect makes the rationale apparent for using it
upfront in the conditioning regimen and/or for consolidation
and maintenance. In one study [43] 19 patients who had
relapsed following RICallo were treated with bortezomib
plus dexamethasone followed by DLI. Sixty eight %
responded, including 10 of them with CR. The 3-year PFS
and OS was 31% and 73% respectively and no severe aGVHD
was seen. Due to its dual effect – preventing GVHD and
preserving GVM – bortezomib should be ideal for inclusion
in the conditioning as has been done in the autologous
transplant setting [45]. Such studies are in progress within
EMN (European Myeloma Network) and EBMT. Oral protea-
some inhibitors such as ixazomib may also have a potential
in the allo setting. Ixazomib has been tried as a single agent
in relapse and in combination with lenalidomide in the
frontline setting. Phase I/II trials are planned using this
agent as maintenance therapy post allo for high risk or
relapsed myeloma [46, 47].
Lenalidomide has been used for maintenance following
allo [48–50], but more frequently for treatment of relapse. Its
use as maintenance is controversial because of induction of
GVHD. In the HOVON 79 study [48] 47% of the patients had
to stop treatment after 2 cycles due to development of acute
GVHD. In another study by Wolschke et al[55_TD$DIFF]. [49] GVHD was
the main reason to discontinue treatment in 29% of the
patients. In a US trial [50] lenalidomide was used following
allo for high risk myeloma. Patients started lenalidomide at
a dose of 10 mg at a median of 96 days post transplant, but
acute GVHD remained an issue with 37% of patients
discontinuing therapy. One year PFS was 68%, which was
encouraging in this high risk group. Lenalidomide has also
been used for treatment of progression, both in the
NMAM2000-EBMT study and in the HOVON study, but its
impact on outcome was not analyzed. In the EBMT study
the survival following relapse was significantly better after
auto/RICallo than after auto/auto [29] perhaps associated
with better response to lenalidomide treatment following
relapse/progression after allo. This would corroborate with
a recent study by Coman et al[55_TD$DIFF]. [51] showing impressive
response rates and a significant association with the devel-
opment of cGVHD after lenalidomide treatment of relapse
following allo. Bensinger [58_TD$DIFF]et al. [52] showed that lenalido-
mide is highly effective in treating relapse/progression after
allo and may be used without inducing severe GVHD if
started later than 6–12 months after transplantation. Thus,lenalidomide may be particularly valuable following allo
both in the maintenance and relapse setting.
Other drugs that may be of value in combination with
allo are the proteasome inhibitor carfilzomib, the immun-
modulator pomalidomide and elotuzomab, an antibody
against CS1 that may have effect in combination with
lenalidomide [53]. These drugs have been proven to be
effective in myeloma and in association with auto, but have
not been used in trials with allo. Defibrotide is another
potentially useful drug, a polydisperse oligonucleotide with
anti-ischemic and anti-thrombotic properties that has been
used to prevent veno-occlusive disease (VOD) associated
with auto and allo and treatment with thalidomide [54–56].
Experimental results suggest that defibrotide has antimye-
loma effects by preventing tumor angiogenesis [56, 57],
however its clinical antimyeloma efficacy is far from clear.
The EBMT and the European Myeloma Network (EMN)
have recently started a phase II allo trial including relapsed/
progressive myeloma patients and using novel drugs both in
the conditioning and as maintenance.Source of stem cells
Originally bone marrow was used as the graft source, but
has practically entirely been substituted for peripheral blood
stem cells since the late 1990[59_TD$DIFF]th. Peripheral blood cells seem
to engraft more rapidly and induce somewhat more chronic
GVHD, but similar PFS and OS as with bone marrow [58].
The number of stem cells should exceed 2 [60_TD$DIFF] 106 kg–1 to
ensure engraftment. The target dose is 4 [61_TD$DIFF] 106 kg–1.Other cell therapies
Donor lymphocyte transfusions (DLI) are effective in about
30% of patients relapsing or progressing following allo with
response lasting more than two years [59–61]. Attempts
have also been made to use DLI to improve the quality of
the response. Escalating dosages of DLI were used in
a European multicenter study of 63 patients with refractory
or relapsed disease after RICallo [62]. Twenty[62_TD$DIFF]-four patients
responded, 12 with CR. The treatment was associated with
acute GVHD in 38%, and chronic GVHD in 43%. In another
study [63] 32 patients who had obtained only partial remis-
sion after allo received DLI. Eight of these patients obtained
hematologic CR and 7 of them a molecular remission. DLI
associated with chronic GVHD seemed in one study to
improve PFS and OS [43]. Thus, DLI is effective in treatment
of relapse and progression, but the risk of inducing severe
GVHD has to be considered.
NK cells are innate cells that have anti-myeloma effect
[64–66]. It has been shown that treatment with expanded
NK cells together with IL-2 significantly improves survival in
a mouse myeloma model [65]. NK cells have with some
success been tried in patients with acute leukemia who
have received allo with haploidentical T-cell-depleted cells
[67] and in a phase I study in terminal cancer, among them
chronic lymphocytic leukemia [68]. Some responses have
been documented. Thus, it is possible that NK cells included
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myeloma.When to perform an allogeneic transplantation
Upfront allo in myeloma has been manly abandoned due to
relatively high TRM. Despite the encouraging results in two
out of [63_TD$DIFF]six upfront studies using combination auto/RICallo
the TRM amounting to about 12–16 per cent is considered
too high despite the higher CR rate and lower relapse/
progression rate as compared to auto or auto/auto. Also,
since the lower relapse progression rate only translated into
better PFS and OS in two of the six prospective studies the
possible cure of a limited fraction of patients is not
considered reason to perform upfront allo. Allo is therefore
presently performed mainly in progression/relapse and only
occasionally upfront in the auto/RICallo setting in high risk
patients (Table I).
Efebra et al[55_TD$DIFF]. [69] included 51 patients with heavily
pretreated relapsed multiple myeloma in a study of RICallo
transplant using a conditioning of melphalan 90–140 mg/
m2 + fludarabin 90–120 mg/m2. ATG was added to patients
who received a transplant from unrelated donors. Trans-
plant-related mortality at one year was 25% and PFS and OS
at two years 19% and 32%, respectively. A retrospective
study by Karlin et al [55_TD$DIFF]. [70] of 23 patients treated in first
relapse with auto/RICallo (conditioning 2 Gy before RICallo)
showed [64_TD$DIFF]an NRM mortality at one year of 17%. The median
event-free survival and OS were 37 and 60 months, respec-
tively. A significant advantage was seen in these patients as
compared to pair matched patients selected from 142 not
allografted ones during the same time period ( [43_TD$DIFF]p = 0.027). In
a study by Shimoni et al[55_TD$DIFF]. [71] of fifty refractory or relapsed
patients transplanted between 2001 [65_TD$DIFF]and 2004 with melpha-
lan–fludarabine based conditioning the estimated seven[66_TD$DIFF]-
year PFS and OS after a median follow-up of 6.4 years were
26% and 34% respectively.
It seems clear that allo should not be performed without
previous induction therapy, preferably a previous auto,
particularly if considered for upfront therapy. In
a retrospective EBMT study [72] 472 patients who received
a planned auto/RICallo were compared to 173 matched
patients who received RICallo without previous auto
between the years 1996 and 2013. After a median follow[54_TD$DIFF]-up
of 93 months the PFS was 34% [67_TD$DIFF]versus 22% and OS 60%
versus 42% respectively at 5 years from transplant. Thus the
auto before the RICallo was important.
In a recent retrospective study of allotransplants in the
EBMT registry Michallet et [118_TD$DIFF]al. [73] found 7333 allotransplants
performed between 1990 and 2012. An analysis of those
4726 patients transplanted from 2004 made it possible to
divide the material into 6 groups based on the time of
transplantation. The best results were found if the trans-
plant was performed [68_TD$DIFF]<8 months after an auto (PFS 42% at
5 y OS 53% at 5y) and particularly if RIC had been used
(median OS 76 m with RIC). However even after several
autos and relapses PFS and OS from allotransplant were
15% and 23% respectively.Should allogeneic transplants be performed at all –
conclusions
Allo has the potential to cure a fraction of patients with
multiple myeloma. Still, high-dose myeloablative condition-
ing has mainly been abandoned due to high TRM. RIC before
allo has significantly lower TRM in the range of 12–16
percent in upfront treatment and is an option for some high
risk patients. Two prospective studies with large numbers of
patients treated with tandem auto/RICallo have shown
superior results after long[69_TD$DIFF]-term follow-up compared to auto
or auto/auto. The auto/RICallo approach may[3_TD$DIFF] overcome poor
risk cytogenetic factors in some patients. Also, in relapsed/
progressive patients auto/RICallo may be a treatment possi-
bility. However, effective induction and/or maintenance
therapy with the novel drugs, like proteasome inhibitors
and immunomodulators, have not been included in most of
the allo studies. Therefore, bortezomib, lenalidomide, carfil-
zomib and pomalidomide should be included in the con-
ditioning and/or consolidation and maintenance in future
trials. Prospective studies using these drugs in all phases
are needed and planned. New cell therapies, such as with
NK cells, that have shown encouraging results in experi-
mental animals, should be tried. Auto/RICallo transplanta-
tion should preferentially be used in clinical trials, but could
also be considered outside such trials in high risk patients
(del17p, del8p and gain 1q) and in progression or relapse
following auto. Allo trials for treatment of multiple mye-
loma in these new settings are in progress in a joint venture
between EMN and EBMT as well as in other groups.Conflict of interest/Konflikt interesu
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